Apexigen
Apexigen was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, acquired by Pyxis Oncology in 2023.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Apexigen, Inc. was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. In August 2023, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the successful completion of its acquisition of Apexigen in an all-stock transaction valued at approximately $10.7 million. The transaction added a validated antibody-discovery platform, a Phase 2 candidate and a royalty stream to Pyxis Oncology, and brought the CD40 agonist sotigalimab (renamed PYX-107) into the combined company's pipeline.
History
Apexigen, Inc. was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. On August 23, 2023, Pyxis Oncology, Inc. (Nasdaq: PYXS) announced the successful completion of its acquisition of Apexigen in an all-stock transaction valued at approximately $10.7 million. The transaction added a validated antibody-discovery platform, a Phase 2 candidate and a royalty stream to Pyxis Oncology, and the combined company's platform included novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site-specific conjugation chemistries, and optimized payloads. The acquisition also brought the CD40 agonist sotigalimab, renamed PYX-107, into the combined company's pipeline.
Products and positioning
Clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology.
sotigalimab (PYX-107)
A CD40 agonist described as a potentially first- and best-in-class candidate with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors; renamed PYX-107 following the acquisition.
Sources5 sources
- 1Pyxis Oncology Successfully Completes Acquisition of Apexigen | Pyxis Oncologyir.pyxisoncology.com
- 2Apexigen (United States)wikidata.org
- 3Apexigen Appoints Biotechnology Financial Executive Herb Cross to Board of Directorsprnewswire.com
- 4Apexigen Appoints Gordon Ringold to its Board of Directorsprnewswire.com
- 5Apexigen Appoints Jakob Dupont to Board of Directorsprnewswire.com
Cite this profile: Cite the canonical profile. /brand-wiki/apexigen-united-states · Editorial policy · How profiles are compiled